. Author manuscript; available in PMC: 2019 Sep 30.

Published in final edited form as: Hepatology. 2018 Sep;68(3):1163–1173. doi: 10.1002/hep.29905

Table 3.

Novel Medical Therapies for Consideration in Biliary Atresia

Bile acid analogues
- –
  Ursodeoxycholic acid
- –
  Norursodeoxycholic acid
- –
  Obeticholic acid (and other FXR agonists)
Agents that decrease the bile acid burden in the liver
- –
  ASBT inhibitors (SHP625, SHP626, A4250, others)
- –
  NTCP inhibitors (Myrcludex B)
- –
  Bile acid sequestrants (Colesevelam, Cholestyramine)
Anti-Inflammatory and immunosuppressive agents
- –
  Monoclonal immunomodulatory agents (anti-TNF, IL-2, IL-6, IL-17A)
- –
  Kinase inhibitors (Tofacitinib, Ibrutinib)
Anti-Fibrotics
- –
  Cenicriviroc
- –
  Pirfenidone
- –
  Nintedanib
- –
  PPAR agonists (Fenofibrate, Pioglitazone, Seladelpar)
Antioxidant and agents that increase GSH
- –
  Cysteamine, N-acetylcysteine
- –
  Vitamin E, Vatiquinone